2025 Q4 -tulosraportti
88 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,21%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 54 | - | - | ||
| 400 | - | - | ||
| 100 | - | - | ||
| 240 | - | - | ||
| 163 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenNow I am a new user, and I think it's great that there is so much debate and so much life on the platform 💪 now to Novo, I see Novo as a long-term investment but I understand there are many day traders / short-term traders in here. How do you see the Novo case? I personally sold a bit of my holdings to see how the stock performs after the financial report and to protect my profit 🔥
·4 t sittenAdvantage of Wegovy pill over Foundayo. A few questions to Claude and he comes up with the following interesting outcome. Foundayo's CYP3A4 / Simvastatin Problem — Short Version 1. What CYP3A4 is A liver enzyme that breaks down ~50% of all prescription drugs. Foundayo is metabolized by it; Wegovy pill is not. 2. The interaction problem Other drugs that block or speed up CYP3A4 will make Foundayo levels too high (toxicity) or too low (no efficacy). The label warns against combining with strong CYP3A4 inhibitors/inducers — and even some dietary supplements like St. John's Wort. 3. The simvastatin warning is the real issue Foundayo's label restricts use with simvastatin doses above 20mg. But many elderly cardiovascular patients are on 40mg or 80mg simvastatin as standard secondary prevention. 4. The doctor's dilemma Faced with a patient on high-dose simvastatin, a doctor must either: switch the statin, lower the statin dose (worse cholesterol control), or just prescribe Wegovy pill instead. The path of least resistance is option 3. 5. Why Medicare Part D matters most Old patients = polypharmacy (5–10 meds). Probability of a CYP3A4 conflict or high-dose statin use is much higher in Medicare patients than in commercial-insurance patients. 6. Medicare is where the volume is Goldman models the Medicare unlock as the swing factor between a $50bn vs $70bn US market by 2030. Whoever wins Medicare wins the next leg of growth. 7. Why it's underappreciated Sell-side debate focuses on efficacy, tolerability, convenience, and pricing. Drug-drug interactions barely get mentioned because clinical trials exclude polypharmacy patients and early IQVIA data is skewed to commercial channels. 8. The investment implication Foundayo's effective addressable market in Medicare is structurally smaller than headline penetration assumptions imply. A quiet, compounding moat for Novo that isn't in consensus models yet — worth tracking in 2026–2027 real-world prescribing data.
·14 t sittenWhy are there always so many who write "it's priced in"? That's almost never true. When the pill came out, several wrote that it wouldn't affect the stock because everyone knew the pill was coming so it was priced in. To which I predicted that it wasn't true and that the stock would explode upwards, which it did, so that disproves all this "it's priced in" stuff.
·5 t sittenIt's a buzzword - or should one say a buzz-phrase. People want to contribute an opinion without taking responsibility - hence all these vague phrases that are devoid of any substantive value: "Perfectly priced", "sentiment-driven", "market sentiment", "the market is always right" etc etc.. Add to that the use of imagery obscure analogies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
88 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,21%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenNow I am a new user, and I think it's great that there is so much debate and so much life on the platform 💪 now to Novo, I see Novo as a long-term investment but I understand there are many day traders / short-term traders in here. How do you see the Novo case? I personally sold a bit of my holdings to see how the stock performs after the financial report and to protect my profit 🔥
- ·4 t sittenAdvantage of Wegovy pill over Foundayo. A few questions to Claude and he comes up with the following interesting outcome. Foundayo's CYP3A4 / Simvastatin Problem — Short Version 1. What CYP3A4 is A liver enzyme that breaks down ~50% of all prescription drugs. Foundayo is metabolized by it; Wegovy pill is not. 2. The interaction problem Other drugs that block or speed up CYP3A4 will make Foundayo levels too high (toxicity) or too low (no efficacy). The label warns against combining with strong CYP3A4 inhibitors/inducers — and even some dietary supplements like St. John's Wort. 3. The simvastatin warning is the real issue Foundayo's label restricts use with simvastatin doses above 20mg. But many elderly cardiovascular patients are on 40mg or 80mg simvastatin as standard secondary prevention. 4. The doctor's dilemma Faced with a patient on high-dose simvastatin, a doctor must either: switch the statin, lower the statin dose (worse cholesterol control), or just prescribe Wegovy pill instead. The path of least resistance is option 3. 5. Why Medicare Part D matters most Old patients = polypharmacy (5–10 meds). Probability of a CYP3A4 conflict or high-dose statin use is much higher in Medicare patients than in commercial-insurance patients. 6. Medicare is where the volume is Goldman models the Medicare unlock as the swing factor between a $50bn vs $70bn US market by 2030. Whoever wins Medicare wins the next leg of growth. 7. Why it's underappreciated Sell-side debate focuses on efficacy, tolerability, convenience, and pricing. Drug-drug interactions barely get mentioned because clinical trials exclude polypharmacy patients and early IQVIA data is skewed to commercial channels. 8. The investment implication Foundayo's effective addressable market in Medicare is structurally smaller than headline penetration assumptions imply. A quiet, compounding moat for Novo that isn't in consensus models yet — worth tracking in 2026–2027 real-world prescribing data.
- ·14 t sittenWhy are there always so many who write "it's priced in"? That's almost never true. When the pill came out, several wrote that it wouldn't affect the stock because everyone knew the pill was coming so it was priced in. To which I predicted that it wasn't true and that the stock would explode upwards, which it did, so that disproves all this "it's priced in" stuff.·5 t sittenIt's a buzzword - or should one say a buzz-phrase. People want to contribute an opinion without taking responsibility - hence all these vague phrases that are devoid of any substantive value: "Perfectly priced", "sentiment-driven", "market sentiment", "the market is always right" etc etc.. Add to that the use of imagery obscure analogies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 54 | - | - | ||
| 400 | - | - | ||
| 100 | - | - | ||
| 240 | - | - | ||
| 163 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
88 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,21%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenNow I am a new user, and I think it's great that there is so much debate and so much life on the platform 💪 now to Novo, I see Novo as a long-term investment but I understand there are many day traders / short-term traders in here. How do you see the Novo case? I personally sold a bit of my holdings to see how the stock performs after the financial report and to protect my profit 🔥
- ·4 t sittenAdvantage of Wegovy pill over Foundayo. A few questions to Claude and he comes up with the following interesting outcome. Foundayo's CYP3A4 / Simvastatin Problem — Short Version 1. What CYP3A4 is A liver enzyme that breaks down ~50% of all prescription drugs. Foundayo is metabolized by it; Wegovy pill is not. 2. The interaction problem Other drugs that block or speed up CYP3A4 will make Foundayo levels too high (toxicity) or too low (no efficacy). The label warns against combining with strong CYP3A4 inhibitors/inducers — and even some dietary supplements like St. John's Wort. 3. The simvastatin warning is the real issue Foundayo's label restricts use with simvastatin doses above 20mg. But many elderly cardiovascular patients are on 40mg or 80mg simvastatin as standard secondary prevention. 4. The doctor's dilemma Faced with a patient on high-dose simvastatin, a doctor must either: switch the statin, lower the statin dose (worse cholesterol control), or just prescribe Wegovy pill instead. The path of least resistance is option 3. 5. Why Medicare Part D matters most Old patients = polypharmacy (5–10 meds). Probability of a CYP3A4 conflict or high-dose statin use is much higher in Medicare patients than in commercial-insurance patients. 6. Medicare is where the volume is Goldman models the Medicare unlock as the swing factor between a $50bn vs $70bn US market by 2030. Whoever wins Medicare wins the next leg of growth. 7. Why it's underappreciated Sell-side debate focuses on efficacy, tolerability, convenience, and pricing. Drug-drug interactions barely get mentioned because clinical trials exclude polypharmacy patients and early IQVIA data is skewed to commercial channels. 8. The investment implication Foundayo's effective addressable market in Medicare is structurally smaller than headline penetration assumptions imply. A quiet, compounding moat for Novo that isn't in consensus models yet — worth tracking in 2026–2027 real-world prescribing data.
- ·14 t sittenWhy are there always so many who write "it's priced in"? That's almost never true. When the pill came out, several wrote that it wouldn't affect the stock because everyone knew the pill was coming so it was priced in. To which I predicted that it wasn't true and that the stock would explode upwards, which it did, so that disproves all this "it's priced in" stuff.·5 t sittenIt's a buzzword - or should one say a buzz-phrase. People want to contribute an opinion without taking responsibility - hence all these vague phrases that are devoid of any substantive value: "Perfectly priced", "sentiment-driven", "market sentiment", "the market is always right" etc etc.. Add to that the use of imagery obscure analogies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 54 | - | - | ||
| 400 | - | - | ||
| 100 | - | - | ||
| 240 | - | - | ||
| 163 | - | - |
Välittäjätilasto
Dataa ei löytynyt